Abhishek D. Garg, Research Associate Professor, Group Leader: Laboratory of Cell Stress & Immunity (CSI) at KU Leuven, shared a post on by GLIOMATCH on LinkedIn:
“Fantastic overview of GLIOMATCH prospective clinical trials by Steven De Vleeschouwer!
Especially looking forward to the results of the Dusseldorf and Oslo trials led by Einar Vik-Mo and Rüdiger Sorg, testing dendritic cell-based vaccination in combination with neoadjuvant or adjuvant checkpoint inhibition with PD-L1.
The design of these trials is directly informed by an innovative negative feedback loop mechanism discovered by our lab. For more, see this Cell Reports Medicine publication.”
Quoting GLIOMATCH‘s post:
“How will GLIOMATCH’s prospective clinical trials contribute to a better understanding of personalised immunotherapy for glioblastoma?
In this GLIOMATCH Explained interview, Prof. Dr Steven De Vleeschouwer, neurosurgeon at UZ Leuven, discusses the planned prospective clinical trials within the project, including participating centres, trial design and research goals.
These exploratory studies are designed to generate scientific insight into how glioblastoma responds to different immunotherapy approaches. They are part of GLIOMATCH’s wider ambition to better understand how patients may be matched to personalised immunotherapy strategies.
Title: Lymph node and tumor-associated PD-L1+ macrophages antagonize dendritic cell vaccines by suppressing CD8+ T cells
Authors: Jenny Sprooten, Isaure Vanmeerbeek, Angeliki Datsi, Jannes Govaerts, Stefan Naulaerts, Raquel S. Laureano, Daniel M. Borràs, Anna Calvet, Vanshika Malviya, Marc Kuballa, Jörg Felsberg, Michael C. Sabel, Marion Rapp, Christiane Knobbe-Thomsen, Peng Liu, Liwei Zhao, Oliver Kepp, Louis Boon, Sabine Tejpar, Jannie Borst, Guido Kroemer, Susan Schlenner, Steven De Vleeschouwer, Rüdiger V. Sorg, Abhishek D. Garg
Read The Full Article
Other articles about immunotherapy on OncoDaily.
